Retractable Technologies Q2 net sales up 73% to $10.4M, operating loss narrows to $5.1M

RETRACTABLE TECHNOLOGIES INC

2025-Q2 EPS reported -$0.36 revenue$18,740,906

Net sales $10.4M in Q2 2025 (+73% YoY); operating loss narrowed to $5.1M from $5.8M.
H1 2025 net sales $18.7M (+37.5% YoY); operating loss widened to $9.8M from $8.7M.
Tariffs: 130% on Chinese needles/syringes; $2.1M spent on tariffs in H1 2025.
Shifted 38% of production to U.S. facility (vs 9% in H1 2024); workforce reductions implemented.
Received $1.9M litigation settlement in May; Q2 net loss only $87K due to investment gains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.